A candidate therapy for fragile X syndrome — developed using Quris’ bio-artificial intelligence clinical prediction platform — will enter…
Articles by Patricia Inácio, PhD
Nova Mentis has filed an application for orphan drug designation with the U.S. Food and Drug Administration (FDA) for…
The U.S. Food and Drug Administration (FDA) has given positive feedback to Actinogen’s pre-investigational new drug (pre-IND) submission regarding…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
Infants with fragile X syndrome who are fed with breast milk for a minimum of one year have a…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
Nova Mentis is launching a clinical study in the U.S. to assess the diversity of gut microbiome — the…
Nova Mentis is expanding its preclinical pipeline to test a psychedelic treatment known as PLZ-1013 in an animal…
A nearly $2 million grant from the National Institute of Mental Health, part of the National Institutes of Health (NIH),…